Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.30 |
| ▸ | FNTB | P49356 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14739684 | 0.76 | CYP1B1 (0.37) | TAAR1FNTAFNTB | |
| SCHEMBL14740374 | 0.72 | KDM4E (0.39) | PARP1 | |
| SCHEMBL14740299 | 0.71 | BCHE (0.46) | — | |
| SCHEMBL19732567 | 0.68 | TAAR1 (0.46) | ALOX15TAAR1HTR1AFNTAFNTB | |
| SCHEMBL1536813 | 0.68 | MPO (0.46) | HTR1A | |
| SCHEMBL29584855 | 0.64 | ALDH1A1 (0.54) | ALOX15TAAR1HTR1A | |
| SCHEMBL1536649 | 0.62 | MPO (0.54) | — | |
| SCHEMBL10643092 | 0.62 | ALOX15 (0.49) | ALOX15TAAR1HTR1AFNTAFNTB | |
| SCHEMBL15329166 | 0.60 | ALOX15 (1.00) | ALOX15TAAR1PARP1EGLN1 | |
| SCHEMBL1953418 | 0.58 | ALOX15 (0.85) | ALOX15TAAR1PARP1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150099769-A1 | PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2015-04-09 | — | — | US | claimed |
| US-8859568-B2 | Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2014-10-14 | — | — | US | claimed |
| US-20130059870-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2013-03-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099769-A1 | PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY | MPO, EPX, XDH | ALOX15 267/4885TAAR1 2653/4885PARP1 741/4885 |
| US-20130059870-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | MPO, CAT, HTT | ALOX15 2414/4885TAAR1 3774/4885PARP1 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.